PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2-Negative

AstraZeneca and Merck's Lynparza (olaparib) Receive EU's Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

AstraZeneca and Merck's Lynparza (olaparib) Receive EU's Approval as a Monotherapy to Treat Germline BRCA-Mutated HER2-Negative Ad...

April 10, 2019

Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

Pfizer's Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated- HER2-Negative LA or MBC

October 11, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us